ArticleHuman vaccines & immunotherapeutics2018
Cross-protection induced by VA-MENGOC-BC® vaccine.
Article in Human vaccines & immunotherapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Trial
- Efficacy of the serogroup BBMJ open · 2026Article
- Harnessing Nanocarriers to Advance Vaccine Development.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- A novel GMMA-based gonococcal vaccine demonstrates functional immune responses in mice.NPJ vaccines · 2025Article
- Isolation of Extracellular Outer Membrane Vesicles (OMVs) fromMolecules (Basel, Switzerland) · 2024Article
- Evaluating vaccine-elicited antibody activities againstInfection and immunity · 2023Article
- Immune responses toFrontiers in immunology · 2023Review
- Preventing invasive meningococcal disease in early infancy.Human vaccines & immunotherapeutics · 2022Review
- Article
- Recent Progress Towards a Gonococcal Vaccine.Frontiers in cellular and infection microbiology · 2022Review
- Vaccine Candidates for the Control and Prevention of the Sexually Transmitted Disease Gonorrhea.Vaccines · 2021Review
- Evaluating the effectiveness of the 4CMenB vaccine against invasive meningococcal disease and gonorrhoea in an infant, child and adolescent program: protocol.Human vaccines & immunotherapeutics · 2021Article
- Review
- The Serogroup B Meningococcal Vaccine Bexsero Elicits Antibodies to Neisseria gonorrhoeae.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Article
- A meningococcal B vaccine induces cross-protection against gonorrhea.Clinical and experimental vaccine research · 2019Article
- Cross-reactivity with Brazilian strains ofTherapeutic advances in vaccines and immunotherapy · 2019Article
- Author reply to VA-MENGOC-BC cross-protection (2018HV0022).Human vaccines & immunotherapeutics · 2018Article
Corrections and comments
- Commented on by
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
I would like to comment on the article "Commentary: Impact of meningococcal group B OMV vaccines, beyond their brief", DOI: 10.1080/21645515.2017.1381810. The author states that meningococcal group B OMVs vaccines -such as VA-MENGOC-BC®- may induce moderate protection against Neisseria gonorrhoeae. I agree. However, the author states that "there was no evidence of effectiveness in the younger children." The effectiveness of VA-MENGOC-BC® in heterologous contexts has been higher than 80% in individuals older than 4 years old, but the effectiveness in younger children should not be undervalued; it has usually been higher than 60%, and results markedly higher when evaluated based on mortality rates. There is strong evidence that VA-MENGOC-BC® may induce cross-protection against heterologous N. meningitidis strains and N. gonorrhoeae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.